Physician profile
Nathan Kumar
NPI 1740856897
$3,151.44
in general payments reported to CMS, 2019-2025
27 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 83% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.68 · 2022: $118 · 2023: $442 · 2024: $510 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Travel and Lodging: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.98 |
| Travel and Lodging | $1,194.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,569.43 | 2025 | |
| Ucb, INC. | $242.89 | 2022-2025 | Briviact, Fintepla |
| Neurocrine Biosciences, INC. | $185.87 | 2022-2024 | Ingrezza |
| Astrazeneca Pharmaceuticals Lp | $165.93 | 2022-2024 | Andexxa, Wainua |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Glaxosmithkline, LLC. | $121.82 | 2023 | |
| Abbvie INC. | $120.18 | 2023 | |
| Globus Medical, INC. | $102.88 | 2025 | Senza, Vyrsa V1 |
| Alnylam Pharmaceuticals INC. | $52.09 | 2023-2025 | Onpattro, Amvuttra |
| Impulse Dynamics (USA) INC. | $45.49 | 2024 | Optimizer |
| Medtronic, INC. | $37.74 | 2025 | Kyphon Express II Kyphopak Tray |
| Otsuka America Pharmaceutical, INC. | $35.03 | 2024-2025 | Rexulti |
| Amgen INC. | $31.61 | 2025 | Otezla |
| Lilly USA, LLC | $28.90 | 2024 | Emgality |
| Biohaven Pharmaceuticals, INC. | $28.68 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $26.17 | 2025 | |
| Lundbeck LLC | $24.90 | 2023 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $24.09 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.24 | 2024 | Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $22.40 | 2025 | |
| Depuy Synthes Sales INC. | $21.66 | 2025 | Va-Lcp, Na, Tfn-Advance |
| Pfizer INC. | $21.51 | 2024 | |
| Averitas Pharma INC. | $20.30 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $19.98 | 2025 | Ultomiris |
| Csl Behring | $19.86 | 2025 | Hizentra |
| Pacira Pharmaceuticals Incorporated | $18.32 | 2023 | Iovera, Zilretta |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.